BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
Number Cited Articles
1
Joseph M. Obeid, Paul R. Kunk, Victor M. Zaydfudim, Timothy N. Bullock, Craig L. Slingluff, Osama E. Rahma. Immunotherapy for hepatocellular carcinoma patients: is it ready for prime time?Cancer Immunology, Immunotherapy 2018; 67(2): 161 doi: 10.1007/s00262-017-2082-z
2
Dass S. Vinay, Byoung S. Kwon. 4-1BB (CD137), an inducible costimulatory receptor, as a specific target for cancer therapyBMB Reports 2014; 47(3): 122 doi: 10.5483/BMBRep.2014.47.3.283
3
Tim F. Greten, Michael P. Manns, Firouzeh Korangy. Immunotherapy of hepatocellular carcinomaJournal of Hepatology 2006; 45(6): 868 doi: 10.1016/j.jhep.2006.09.004
4
Álvaro Teijeira, Asís Palazón, Saray Garasa, Diego Marré, Cristina Aubá, Anne Rogel, Ohiana Murillo, Iván Martínez‐Forero, François Lang, Ignacio Melero, Ana Rouzaut. CD137 on inflamed lymphatic endothelial cells enhances CCL21‐guided migration of dendritic cellsThe FASEB Journal 2012; 26(8): 3380 doi: 10.1096/fj.11-201061
5
Lingyun Ye, Keyi Jia, Lei Wang, Wei Li, Bin Chen, Yu Liu, Hao Wang, Sha Zhao, Yayi He, Caicun Zhou. CD137, an attractive candidate for the immunotherapy of lung cancerCancer Science 2020; 111(5): 1461 doi: 10.1111/cas.14354
6
Dass S. Vinay, Kiweon Cha, Byoung S. Kwon. Dual immunoregulatory pathways of 4-1BB signalingJournal of Molecular Medicine 2006; 84(9): 726 doi: 10.1007/s00109-006-0072-2
7
Thomas C Wirth. Spontaneous and therapeutic immune responses in hepatocellular carcinoma: implications for current and future immunotherapiesExpert Review of Gastroenterology & Hepatology 2014; 8(1): 101 doi: 10.1586/17474124.2014.862497
8
Herbert Schwarz. Biological activities of reverse signal transduction through CD137 ligandJournal of Leukocyte Biology 2005; 77(3): 281 doi: 10.1189/jlb.0904558